We calculated the difference of HNRNPA2B1 expression across samples representing different clinical stages for each type of tumor, and used unpaired Wilcoxon rank-sum and signed rank tests to analyze the significance of the difference, using Kruskal Test to test the difference of multiple groups of samples, we observed significant differences in seven cancers, such as BRCA, ESCA, STES, SARC, STAD, PRAD, and OV (Supplementary figure 1). This evidence concerns the gene HNRNPA2B1 and cancer.